Medicinal Products

1860. Deputy Paul Lawless asked the Minister for Health the way in which the National Rare Disease Strategy 2025–2030 and 2026 IPHA Framework Agreement, especially the 180-day timeline, applies to the negotiations for skyclarys; and to resolve this urgent unmet need without further postponement. [19312/26]

1886. Deputy Alan Kelly asked the Minister for Health if she will commit to make the treatment omaveloxolone available for suffers of Friedreich’s ataxia; and if she will make a statement on the matter. [19427/26]

1901. Deputy Barry Ward asked the Minister for Health further to Parliamentary Question No. 788 of 3 March 2026, the position regarding a timeline for the completion of the assessment of the proposal for reimbursement of Skyclarys for patients with Friedreich’s ataxia; and if she will make a statement on the matter. [19446/26]

1902. Deputy Barry Ward asked the Minister for Health if any submissions can be consider as part of the assessment of the proposal for reimbursement of Skyclarys for patients with Friedreich’s ataxia; and if she will make a statement on the matter. [19447/26]

1903. Deputy Barry Ward asked the Minister for Health if she will facilitate a meeting with the campaign group that are seeking State funded reimbursement of skyclarys for patients with Friedreich’s ataxia; and if she will make a statement on the matter. [19448/26]

1904. Deputy Barry Ward asked the Minister for Health the position regarding any procedure that would allow for a meeting between the relevant Department staff and the campaign group that are seeking State funded reimbursement of skyclarys for patients with Friedreich’s ataxia; and if she will make a statement on the matter. [19449/26]

1915. Deputy Keira Keogh asked the Minister for Health the position regarding the availability of Skyclarys (Omaveloxolone) for those who are living with Friedreich’s ataxia; and if she will make a statement on the matter. [19485/26]

1935. Deputy Robert Troy asked the Minister for Health the position regarding the price negotiations on the approval of Skyclarys for the treatment of Friedreich’s Ataxia; the specific steps that are being taken to ensure the HSE considers the time critical nature of Friedreich’s ataxia during the current price negotiations. [19639/26]

1936. Deputy Robert Troy asked the Minister for Health if the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA framework agreement, which aims for a 180 day decision timeline, are being applied in price negotiations for Skyclarys in the treatment of Freidreich’s ataxia. [19640/26]

1939. Deputy Seán Crowe asked the Minister for Health if a pricing and reimbursement application has been received by the HSE for zolbetuximab (Vyloy®); if the national assessment and decision process has begun; and if she will make a statement on the matter. [19668/26]

1949. Deputy Micheál Carrigy asked the Minister for Health the specific steps being taken to ensure the HSE considers the 'time-critical' nature of FA during the current price negotiations for Skyclarys; the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement (which aims for a 180-day decision timeline) are being applied to this specif…

1964. Deputy John Connolly asked the Minister for Health the specific actions being taken to ensure that the HSE recognises and responds to the time-critical nature of Friedreich’s ataxia in the ongoing price negotiations for Skyclarys (Omaveloxolone); the way in which the commitments contained within the National Rare Disease Strategy 2025–2030 and the 2026 IPHA Framework Agreement, including the…

1970. Deputy Pearse Doherty asked the Minister for Health if consideration has been given to prioritise the reimbursement of Skyclarys (omaveloxolone) under the current drugs reimbursement process for the treatment for Friedreich's Ataxia; and if she will make a statement on the matter. [19753/26]

1974. Deputy Donna McGettigan asked the Minister for Health the timeline for a decision on the Acarizax reimbursement application (HSE100082) is expected; the stage the review process of the application is currently at; whether any interim supports or exceptional access arrangements may be available for patients currently prescribed this treatment; and if she will make a statement on the matter. […

1983. Deputy Conor Sheehan asked the Minister for Health for an update on the negotiations around the inclusion of the shingles vaccine in the national immunisation programme; when she will make a decision on whether to include the shingles vaccine in the national immunisation programme; and if she will make a statement on the matter. [19852/26]

2034. Deputy Ruth Coppinger asked the Minister for Health the steps she will take to ensure that givinostat is available at the earliest opportunity to sufferers of Duchenne muscular dystrophy; and if she will make a statement on the matter. [20013/26]

2041. Deputy Carol Nolan asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease and represents a clear unmet need under the National Rare Disease Strategy 2025-2030; and if she will make a statement on the matter. [20045/26]

2042. Deputy Carol Nolan asked the Minister for Health if she believes the current delay aligns with the "equitable access" promised in the newly launched National Rare Disease Strategy 2025-2030; and if she will make a statement on the matter. [20046/26]

2066. Deputy Carol Nolan asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for Friedreich's ataxia disease and represents a clear unmet need under the National Rare Disease Strategy 2025-2030; if she believes the current delay in concluding negotiations contr…

2072. Deputy Denise Mitchell asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease and represents a clear unmet need under the National Rare Disease Strategy 2025-2030; if she believes the current delay aligns with the "equitable acce…

2073. Deputy Claire Kerrane asked the Minister for Health the steps being taken to ensure that the HSE recognises and responds to the time-critical nature of Friedreichs Ataxia during the current price negotiations for Skyclarys; and if she will make a statement on the matter. [20158/26]

2074. Deputy Claire Kerrane asked the Minister for Health the commitments outlined in the National Rare Disease Strategy 2025-2030, and the 2026 IPHA Framework Agreement which aims for a 180-day decision timeline being applied in the case of ensuring Friedreichs Ataxia patients in Ireland can access Skyclarys; and to prevent further delays in addressing this clear unmet need; and if she will make …

2088. Deputy Louis O'Hara asked the Minister for Health the steps being taken to ensure that the HSE recognises and responds to the time-critical nature of Friedreich's ataxia during the current price negotiations for Skyclarys; the way in which the commitments outlined in the National Rare Disease Strategy 2025-2030, and the 2026 IPHA Framework Agreement which aims for a 180-day decision timeline…

2091. Deputy Michael Fitzmaurice asked the Minister for Health the steps being taken to ensure that the HSE recognises and responds to the time-critical nature of Friedreich's ataxia during the current price negotiations for Skyclarys; and if she will make a statement on the matter. [20251/26]

2092. Deputy Michael Fitzmaurice asked the Minister for Health the way in which the commitments outlined in the National Rare Disease Strategy 2025-2030, and the 2026 IPHA Framework Agreement, which aims for a 180-day decision timeline, being applied in this case to prevent further delays in addressing this clear unmet need; and if she will make a statement on the matter. [20252/26]